Searched for
ZYDUS LIFESCIENCES STOCK ANALYSIS
Stock Radar: HCC stock breaks out from a triangle formation; time to buy?Hindustan Construction Company Ltd (HCC) stock has broken out of a triangular pattern, signaling potential for upward movement. Experts sug...- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Regulator, cos discuss price hike for some cancer drugsIndia's drug pricing authority may soon approve a price hike for vital platinum-based cancer medicines. These drugs, including carboplatin ...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Momentum in mid-& small-caps to fuel fresh derivatives playsMid and small-cap stocks are outperforming, driving activity in stock futures. Analysts highlight GE Vernova T&D India, CAMS, Suzlon Energy...
- Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoYSupriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surgin...
- Stocks in news: RIL, Coal India, IDFC First Bank, Zydus Life, ONGCMarkets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
- Zydus Lifesciences hikes share buyback price to Rs 1,260 per share, lowers share countZydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The tota...
- Zydus Lifesciences buyback alert! Last date to buy shares to participate in Rs 1,100 crore buyback at 7% premiumInvestors must purchase Zydus Lifesciences shares by Wednesday, May 27, to be eligible for the Rs 1,100 crore buyback, as the record date i...
- Stock Radar: Zydus Lifesciences stock breaks out from inverse head & shoulder pattern to hit fresh 52-week high; time to buy?Zydus Lifesciences Ltd. broke out from an inverse head & shoulder pattern, hitting fresh 52-week highs and suggesting continued momentum. E...
- Sakar Healthcare partners with Zydus Lifesciences for GCC MarketsSakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks ...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other detailsZydus Lifesciences is launching its largest share buyback program to date. The company plans to repurchase shares worth Rs 1,100 crore. Thi...
- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
Load More
